Brittany O'connor, MS, CCC-SLP | |
717 N Liberty St, Boise, ID 83704-9342 | |
(208) 367-8989 | |
Not Available |
Full Name | Brittany O'connor |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 717 N Liberty St, Boise, Idaho |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194362541 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | SLP-3581 (Idaho) | Primary |
Mailing Address | Practice Location Address |
---|---|
Brittany O'connor, MS, CCC-SLP 2306 W Bannock St, Boise, ID 83702-4830 Ph: (360) 213-4540 | Brittany O'connor, MS, CCC-SLP 717 N Liberty St, Boise, ID 83704-9342 Ph: (208) 367-8989 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
Both moderate-to-large weight gain and weight loss, defined as a change of 10% or more in weight, among middle-aged and elderly Chinese Singaporeans are linked to increased risk of death, particularly from cardiovascular disease, and between them, weight loss was associated with higher risk than weight gain.
Repros Therapeutics Inc. today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.
› Verified 4 days ago
Jennifer Dahms, MS/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2995 N Cole Rd, Suite 130, Boise, ID 83704 Phone: 208-559-2348 Fax: 888-559-4660 | |
Lauren Rose Addison, M.S. SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 8620 W Emerald St Ste 100, Boise, ID 83704 Phone: 208-898-1368 | |
Kelli Shaw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3115 N Sycamore Dr, Boise, ID 83703 Phone: 208-401-6401 | |
Christy Baltazor, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Megan Patrick, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2127 W Overland Rd, Boise, ID 83705 Phone: 208-321-4898 | |
Emily Chapman, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8860 W Evening Star Ln, Boise, ID 83709 Phone: 814-873-9144 | |
Kimberly Degraw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 901 N Curtis Rd Ste 204, Boise, ID 83706 Phone: 208-367-8282 |